The Israeli-American biotechnology company is also currently conducting a Phase III clinical trial for the treatment of amyotrophic lateral sclerosis (ALS).

Lonza Pharma & Biotech launched a new collaborative center for research into new technologies for medicine manufacturing.

The company and its partners plan to invest in up to four early-stage Israeli startups a year over five years